Insider Buying: SIGA Technologies, Inc. (OTCMKTS:SIGA) CFO Purchases 5,000 Shares of Stock

SIGA Technologies, Inc. (OTCMKTS:SIGA) CFO Daniel J. Luckshire bought 5,000 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were bought at an average price of $4.34 per share, with a total value of $21,700.00.

Shares of SIGA stock opened at $4.55 on Friday. The company has a 50-day simple moving average of $5.12 and a 200 day simple moving average of $5.35. SIGA Technologies, Inc. has a 52 week low of $4.28 and a 52 week high of $8.09.

SIGA Technologies (OTCMKTS:SIGA) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.03) EPS for the quarter. The company had revenue of $8.11 million for the quarter.

Several large investors have recently modified their holdings of the company. JPMorgan Chase & Co. grew its stake in shares of SIGA Technologies by 19.5% in the second quarter. JPMorgan Chase & Co. now owns 15,131 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 2,466 shares in the last quarter. Wells Fargo & Company MN raised its stake in SIGA Technologies by 5.0% in the 2nd quarter. Wells Fargo & Company MN now owns 113,622 shares of the biotechnology company’s stock worth $645,000 after purchasing an additional 5,421 shares in the last quarter. Bank of Montreal Can acquired a new stake in SIGA Technologies in the 2nd quarter worth about $32,000. Aperio Group LLC raised its stake in SIGA Technologies by 47.3% in the 2nd quarter. Aperio Group LLC now owns 18,946 shares of the biotechnology company’s stock worth $108,000 after purchasing an additional 6,088 shares in the last quarter. Finally, Strs Ohio boosted its holdings in SIGA Technologies by 7.2% in the 2nd quarter. Strs Ohio now owns 110,100 shares of the biotechnology company’s stock valued at $625,000 after purchasing an additional 7,400 shares during the period. Institutional investors own 6.66% of the company’s stock.

SIGA Technologies Company Profile

SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).

Further Reading: Overbought

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit